EUCTR2005-003771-20-DE进行中（未招募）不适用
A 12-week, double-blind, randomised, placebo-controlled, multicentre trial to evaluate efficacy and tolerability of Antistax® film-coated tablets, 360 mg/day orally, in male and female patients suffering from chronic venous insufficiency - Antistax-Study
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female
- •2. 18 years of age or older
- •3. CVI, Clinical Class 3 and Class 4a according to the CEAP classification:
- •4. Presence of oedema determined by a pretibial pit after a 30 seconds pressure with the thumb documented by a photo and presence of varicose veins and/or presence of at least one of the following conditions: hyperpigmentation, eczema or atrophy blanche.
- •5. Stable and reproducible status of swelling documented by a difference of less than 150 g between screening and baseline as determined by water displacement method
- •6. Willing and able to give written informed consent prior to participation in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A. Concomitant diseases
- •1. Decompensated cardiac insufficiency according to the New York Heart Association (NYHA) classification III and IV for cardiac patients,
- •2. Oedema not due to venous disease of the legs (e.g., latent cardiac insufficiency, renal insufficiency, lymphoedema, etc)
- •3. Severe skin changes, e.g. lipodermatosclerosis or ulcus
- •4. Peripheral arterial disease (ankle/arm pressure index < 0.9)
- •5. Current acute phlebitis or thrombosis. Patients with a healed postthrombotic syndrome, who do not currently receive a medical treatment, can be included in the study.
- •6. Renal insufficiency
- •7. Liver disease
- •8. Other diseases: hyper- or hypocalcaemia, malignancies
- •9. Anamnestic indications of diabetic microangiopathy or polyneuropathy
- •10. Drug and/or alcohol abuse
- •11. Severe climacteric complaints: changes in, or initiation with post-menopausal hormone replacement therapy within the last 3 months
- •12. Immobility
- •13. Avalvulia
- •14. Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans)
- •15. State after pulmonary embolism
- •16. Recognised hypersensitivity to the trial drug ingredients
- •17. Current florid venous ulcus
- •18. Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compression treatment, phlebectomy, etc.
- •B. Previous treatments
- •1. Patients who are on compression therapy and/or are wearing support stockings and who optimally benefit from these measures. If the compression therapy / wearing of support stockings is stopped two weeks prior to the intake of study medication, the patient can be included.
- •2. Treatment with venous drugs within the last 2 weeks prior to the intake of study medication
- •3. Changes in or unstable response to treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors, calcium antagonists, or laxatives within the last 2 weeks prior to the intake of study medication
- •C. Concomitant treatment/non-drug therapy exclusion criteria
- •1. Other venous drugs apart from the trial medication
- •2. Venous surgery or sclerotherapy within the last 12 month at the leg used for volumetry
- •3. Extensive use of laxatives
- •4. Major surgery requiring full anaesthesia
- •5. Nitrates, ergot alkaloids and diuretics
- •D. Other exclusion criteria
- •1. Previously studied under this protocol
- •2. Participation in another clinical trial within the previous 90 days or during the present study
- •3. Patient is investigator, co-investigator, study nurse in this study or is a relative of the investigator, co-investigator, or study nurse in this study
- •4. Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only)
- •5. Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial
- •6. Patients in a bad general health state according to the investigator’s judgement
研究者
相似试验
进行中（未招募）
不适用
A 12-week, double-blind, randomised, placebo-controlled, multicentre trial to evaluate efficacy and tolerability of Antistax® film-coated tablets, 720mg/day orally, in male and female patients suffering from chronic venous insufficiency.chronic venous insufficiencyMedDRA version: 9.1Level: LLTClassification code 10066682Term: Chronic venous insufficiencyEUCTR2008-003932-40-DEBoerhinger Ingelheim Pharma GmbH & Co.KG
进行中（未招募）
不适用
A 12-week, double-blind, randomised, placebo-controlled, multicentre trial to evaluate efficacy and tolerability of Antistax® film-coated tablets, 360 mg/day orally, in male and female patients suffering from chronic venous insufficiency - Antistax studychronic venous incufficiencyMedDRA version: 8.1Level: LLTClassification code 10047220EUCTR2005-003771-20-CZBoehringer Ingelheim GmbH200
进行中（未招募）
不适用
A 12-week, double-blind, randomised, placebo-controlled, multicentre trial to evaluate efficacy and tolerability of Antistax® film-coated tablets, 360 mg/day orally, in male and female patients suffering from chronic venous insufficiency - Antistax-Studychronic venous insufficiencyMedDRA version: 8.1Level: LLTClassification code 10047220EUCTR2005-003771-20-ATBoehringer Ingelheim GmbH200
进行中（未招募）
不适用
A 12-week, randomised, double-blind, placebo-controlled study to assess the anti-inflammatory activity, efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD).Chronic obstructive pulmonary diseaseMedDRA version: 9.1Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseEUCTR2007-004033-42-EEGlaxoSmithKline Research and Development Ltd740
进行中（未招募）
1 期
A 12-week, randomised, double-blind, placebo-controlled study to assess the anti-inflammatory activity, efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD).Chronic obstructive pulmonary diseaseMedDRA version: 9.1Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseEUCTR2007-004033-42-NLGlaxoSmithKline Research and Development Ltd